Resumen de Prognostic value of a novel myeloid‑to‑lymphoid ratio biomarker in advanced gastric cancer
Yuting Pan, Yue Ma, Guanghai Dai
Background Currently, immune checkpoint inhibitors (ICIs) have excellent performance in the clinical treatment of advanced gastric cancer (AGC). However, precisely selecting AGC patients who can beneft from immunotherapy is an urgent diffculty. In this study, we investigated the immunoprognostic role of myeloid-to-lymphocyte ratio (M:L) in AGC patients.
Methods We collected information on 268 AGC patients who were hospitalized in the Department of Medical Oncology of PLA General Hospital from December 2014 to May 2021. The patients were divided into low M: L group (<3.76) and high M:L group (≥3.76). Survival diferences between diferent M: L level groups at baseline and after treatment were analyzed by methods such as Kaplan–Meier, Cox or Logistic regression model.
Results Progression free survival (PFS) (5.8 months vs. 3.4 months, p=0.001) and overall survival (OS) (14.1 months vs. 9.0 months, p=0.001) were signifcantly longer in the low M:L group than in the high M:L group. After analyses of Cox regression modeling it was concluded that M:L was an independent prognostic factor for PFS (HR 1.371 95%CI 1.057–1.777 p=0.017) and OS (HR 1.352 95%CI 1.003–1.824 p=0.048), respectively. Subsequent subgroup analyses performed across immunotherapy lines, regimens, PD-1 inhibitor agents, and age groups revealed a poorer prognosis in the high M:L group. Notably, an increase in the value of M:L after treatment signifcantly increased the risk of poor prognosis.
Conclusions M:L≥3.76 is associated with poor prognostic outcomes in AGC patients receiving immunotherapy and may be a predictive biomarker of prognosis. This result needs to be confrmed by larger prospective studies.
